Instil Bio, Inc. — 2021 Form 10-K
Business context and reporting period. This annual filing covers the fiscal year ended December 31, 2021. Instil Bio is a clinical-stage biopharmaceutical company developing autologous tumor-infiltrating lymphocyte (TIL) cell therapies. It has no approved products and has not generated product-sales revenue.
Financial performance and liquidity
| Metric | 2021 | 2020 |
|---|---|---|
| Revenue | $0 | $138,000 |
| Research and development expense | $107.3 million | $19.4 million |
| General and administrative expense | $48.3 million | $14.4 million |
| Operating loss | $155.6 million | $33.6 million |
| Net loss | $156.8 million | $37.7 million |
| Net cash used in operating activities | $122.1 million | $29.6 million |
- At year-end, cash and cash equivalents were $37.6 million, restricted cash was $0.5 million, and marketable securities were $416.5 million, for total cash, restricted cash and marketable securities of $454.6 million.
- Total assets were $610.0 million and total liabilities were $54.8 million. The filing reports no borrowings or other debt balance.
- Financing cash flow was $393.2 million, mainly from $339.0 million net IPO proceeds and $52.5 million net proceeds from Series C preferred stock. Investing cash flow was an outflow of $474.4 million, including $57.8 million of property and equipment purchases and net purchases of marketable securities.
- Management estimated existing liquidity would fund operating expenses and capital requirements into 2023; this estimate depends on assumptions and spending could exceed expectations.
Changes versus the prior comparable period
- Net loss increased by $119.1 million year over year as operating expenses expanded to advance clinical programs, increase staffing and develop manufacturing facilities.
- R&D expense rose $87.9 million, driven by personnel and related costs, clinical and manufacturing activity, and facilities and overhead. G&A expense rose $33.9 million, including higher personnel, consulting and insurance costs.
- Revenue fell from $138,000 to zero; the 2020 revenue came from a clinical-material storage and processing services agreement that ended during 2020.
- Operating cash use increased by $92.5 million. The company completed its IPO in March 2021, and preferred shares converted into common stock.
Outlook, commentary and key risks
- ITIL-168: The company initiated its global Phase 2 DELTA-1 trial for advanced melanoma in 2021, with topline safety and efficacy data expected in 2023. The trial is intended to inform a potential BLA submission if successful. Phase 1 studies in additional cancer types were planned for 2022.
- ITIL-306: Management planned to file an IND and initiate a Phase 1 trial in 2022 for its engineered CoStAR-TIL candidate. These are forward-looking plans, not reported outcomes.
- Clinical evidence caveat: The cited UK compassionate-use results—21 patients, 67% overall response rate and 19% complete response rate—came from a TIL product made with a prior version of the ITIL-168 process. The filing cautions these results do not establish safety or efficacy; adverse events were not systematically graded or consistently attributed.
- Manufacturing and capital commitments: The company disclosed that technology transfer to Tarzana was underway and that it had not yet successfully produced an ITIL-168 batch there. Year-end commitments included $63.2 million for the Tarzana development project, approximately $34.6 million in potential future clinical-trial services, and $10.2 million in minimum lease payments.
- Principal risks: Clinical and regulatory outcomes are uncertain; the company has no commercial products and expects continuing losses and additional funding needs. Manufacturing scale-up, comparability between sites, trial enrollment, competition, reimbursement, intellectual-property protection, COVID-19 impacts and access to capital are among the disclosed risks.
- The financial statements received an unqualified audit opinion. Management reported effective disclosure controls, but the company did not provide an auditor attestation or management assessment of internal control over financial reporting, citing the transition period for newly public companies.
Important facts for investors to verify
- Whether ITIL-168 enrollment, safety and efficacy support the expected 2023 data timing and any registration-enabling strategy.
- Whether Tarzana manufacturing transfer, batch production and comparability testing succeed, and whether planned facility capacity is achieved.
- Actual cash burn, construction and clinical commitments, and whether liquidity remains sufficient beyond management’s stated runway into 2023.
- Progress and timing of ITIL-168 studies in additional indications and the ITIL-306 IND and first-in-human program.
- How clinical results compare with the earlier compassionate-use experience, including systematically collected safety data and the relevance of the prior manufacturing process.